OneSource Specialty Pharma Limited (BOM:544292)
India · Delayed Price · Currency is INR 1,814.55
+21.70 (1.21%)
At close: May 29, 2026
BOM:544292 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
Operating Revenue | 14,216 | 14,449 | 1,719 | 387.14 |
Other Revenue | 150.22 | - | - | - |
| 14,366 | 14,449 | 1,719 | 387.14 | |
Revenue Growth (YoY) | -0.57% | 740.43% | 344.07% | - |
Cost of Revenue | 4,446 | 4,966 | 852.13 | 336.43 |
Gross Profit | 9,920 | 9,483 | 867.06 | 50.71 |
Selling, General & Admin | 2,423 | 2,324 | 825.5 | 749.29 |
Other Operating Expenses | 4,305 | 2,514 | 844.61 | 808.7 |
Operating Expenses | 9,518 | 7,577 | 2,433 | 2,215 |
Operating Income | 401.51 | 1,906 | -1,566 | -2,164 |
Interest Expense | -1,222 | -1,541 | -853.99 | -401.06 |
Interest & Investment Income | - | 149.44 | 17.65 | 14.67 |
Currency Exchange Gain (Loss) | - | 27.19 | -5.75 | -91.59 |
Other Non Operating Income (Expenses) | - | -112.1 | -38.97 | -73.21 |
EBT Excluding Unusual Items | -820.34 | 428.87 | -2,447 | -2,715 |
Gain (Loss) on Sale of Investments | - | 11.17 | 7.57 | 1.15 |
Gain (Loss) on Sale of Assets | - | -2.25 | -58.08 | - |
Asset Writedown | - | -1,108 | -1,159 | -1,451 |
Other Unusual Items | -99.27 | - | - | - |
Pretax Income | -919.61 | -670.66 | -3,657 | -4,156 |
Income Tax Expense | -181.58 | -497.85 | - | - |
Earnings From Continuing Operations | -738.03 | -172.81 | -3,657 | -4,156 |
Earnings From Discontinued Operations | - | -6.9 | -254.68 | -3,842 |
Net Income | -738.03 | -179.71 | -3,912 | -7,998 |
Net Income to Common | -738.03 | -179.71 | -3,912 | -7,998 |
Shares Outstanding (Basic) | 115 | 110 | 42 | 40 |
Shares Outstanding (Diluted) | 115 | 110 | 42 | 40 |
Shares Change (YoY) | 3.81% | 165.73% | 4.34% | - |
EPS (Basic) | -6.44 | -1.63 | -94.15 | -200.87 |
EPS (Diluted) | -6.44 | -1.63 | -94.15 | -200.87 |
Free Cash Flow | -5,605 | -1,960 | -1,710 | -2,068 |
Free Cash Flow Per Share | -48.91 | -17.75 | -41.15 | -51.93 |
Gross Margin | 69.05% | 65.63% | 50.43% | 13.10% |
Operating Margin | 2.79% | 13.19% | -91.09% | -558.99% |
Profit Margin | -5.14% | -1.24% | -227.53% | -2066.00% |
Free Cash Flow Margin | -39.02% | -13.57% | -99.45% | -534.07% |
EBITDA | 3,192 | 4,367 | -665.97 | -1,507 |
EBITDA Margin | 22.22% | 30.23% | -38.74% | - |
D&A For EBITDA | 2,791 | 2,462 | 900.01 | 656.8 |
EBIT | 401.51 | 1,906 | -1,566 | -2,164 |
EBIT Margin | 2.79% | 13.19% | -91.09% | - |
Revenue as Reported | 14,366 | 14,623 | 1,761 | 414.06 |
Advertising Expenses | - | 18.2 | 5.04 | 10.44 |